High-Dose Flu Vaccine Tied to 55% Lower Alzheimer's Incidence in 65+ Cohort, Neurology Study Reports

The Neurology paper analyzed insurance claims from more than 1.2 million U.S. seniors and compared Alzheimer's incidence between recipients of high-dose (60 µg antigen) versus standard-dose (15 µg) inactivated flu vaccines. High-dose recipients showed markedly lower cumulative incidence, consistent with the hypothesis that stronger antigenic stimulation may reduce chronic neuroinflammation or enhance immune surveillance of misfolded proteins. This builds on the team's 2022 observational work linking any flu vaccination to reduced Alzheimer's risk and aligns with emerging evidence that repeated immune challenges can modulate microglial activation.

Prior vaccine-Alzheimer's studies were limited by healthy-user bias and lacked dose stratification; the current design used propensity-score matching and dose-specific CPT codes to mitigate confounding. Still, the observational nature leaves open the possibility that unmeasured factors such as healthcare engagement drove both vaccine choice and lower dementia rates. An ongoing phase 3 randomized trial of high-dose versus standard-dose flu vaccine with incident dementia as a secondary endpoint will be critical to confirm causality.

If replicated, the finding could shift CDC recommendations toward routine high-dose preference for all adults 65+, potentially altering annual vaccination uptake patterns and prompting similar dose-response investigations for other adult vaccines. Health systems may begin tracking Alzheimer's incidence as a population-level vaccine outcome metric within five years.